Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Program for the Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes. Evaluation of the Efficacy of the Life-style Modification and the Life-style Modification in Conjunction With Metformin, in the Prevention of Diabetes Mellitus Development in a Population of Women Who Had Expired a Gestational Diabetes - a Multicenter, Randomized, Double Blind Study.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00265746
• Other study ID #: KBN Nr 2 P05001 28
• Status: Withdrawn
• Phase: Phase 4
• Start date: November 2005

Study information

• Verified date: March 2019
• Source: Medical Universtity of Lodz
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gestational diabetes is also a strong risk factor for the development of diabetes mellitus at a later stage of life in previous GDM woman. Among all the risk factors of diabetes mellitus, the experience of gestational diabetes is the strongest one. The incidence of various forms of diabetes in this group balances from 10 to 60% over a period from 2 to 10 years.

The aim of this study is a comparison of the efficacy of life style modification and life style modification in conjunction with metformin administration, in a population of women, who had already experienced gestational diabetes.

Description:

Gestational diabetes mellitus (GDM) is one of the most frequent metabolic disorders occurring during pregnancy that complicates both, the course of pregnancy and the delivery and is also responsible for many fetal complications. Gestational diabetes is also a strong risk factor for the development of diabetes mellitus at a later stage of life in previous GDM woman. Among all the risk factors of diabetes mellitus, the experience of gestational diabetes is the strongest one. The incidence of various forms of diabetes in this group balances from 10 to 60% over a period from 2 to 10 years.

Presently, in the literature, there are described new, more efficient methods of diabetes prevention in groups with a high risk of this disorder, which involve both, a modification of the life style and pharmacotherapy. The use of metformin in patients with a impaired glucose tolerance, resulted in a ca. 30% reduction of the diabetes incidence rate.

The aim of this study is a comparison of the efficacy of life style modification and life style modification in conjunction with metformin administration, in a population of women, who had already experienced gestational diabetes.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: January 1, 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• GDM - experienced during pregnancy (diagnosis of GDM according to WHO-criteria)

• Breast-feeding of the newborn finished (lactation finished)

• Actual BMI >= 25 kg/ m2

• Written consent for participation in the study

• A hitherto prevailing good cooperation with the patient

Exclusion Criteria:

• Cholestasis during the past pregnancy

• Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage,jaundice of unknown etiology)

• Serum ASPAT and/or ALAT level exceeding more than twice normal laboratory values

• Pregnancy planned during the coming two years

• Presence of contradictions for metformin administration according to demands of the Drug Admission Committee in Poland

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetes, Gestational
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Metformin

Behavioral:
• Lifestyle intervention - diet, physical activity

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Medical Universtity of Lodz

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of type 2 diabetes mellitus.
Secondary	Incidence of IGT